Effects of sex and age on pyridostigmine potentiation of growth hormone-releasing hormone-induced growth hormone release

Salvatore M. Corsello, Anna Tofani, Silvia Della Casa, Carlo A. Rota, Rosa Sciuto, Simonetta Colasanti, Angela Barini, Antonino Barbarino

Research output: Contribution to journalArticle

Abstract

Previous studies have shown that pyridostigmine (PD) is capable of increasing the growth GHRH hormone (GH) response to GH-releasing hormone (GHRH) in young healthy subjects. In Pyridostigmine order to investigate the influence of age and sex on the PD potentiation of GHRH-induced GH release, we have studied the GH response to GHRH (50 μ gi.v.) 1 h after oral administration of placebo or PD (60 mg) in 8 young healthy men (aged 19-28 years) and 8 age-matched young women (aged 18-25 years) during the follicular phase of the menstrual cycle, as well as in 8 postmenopausal women (aged 57-62 years) and 8 age-matched elderly men (aged 56-64 years). In the same subjects the effect of PD alone (60 mg p.o.) was also studied. Furthermore, in 6 postmenopausal women and 6 elderly men, the effect of a 30-mg PD oral dose on GH secretion and GH response to GHRH was evaluated with a similar protocol. The GH responses (mean ± SE) to GHRH + placebo were similar in young men (peak 20.1 ± 2 ng/ml. AUC 1, 250± 113 ng/ml/min) and women (peak 29.3 ± 2.3 tig/ml, AUC 1, 769 ± 305 ng/ml/min). PD 60 mg was capable of significantly increasing the GH response to GHRH in young men (peak 43.5± 5.1 ng/ml, AUC 3, 734± 472 ng/ml/min, p<0.005) but not in women (peak 39± 2.3 ng/ml, AUC 2.479± 205 ng/ml/min). Hie GH responses to GHRH ± placebo were also similar in postmenopausal women (peak 6.2± 0.7 ng/ml, AUC 540± 80 ng/ml/min) and age-matched men (peak 11.3± 0.6 ng/ml, AUC 763 ± 73 ng/ml/min) although these responses were significantly decreased when compared to those observed in young individuals. PD 60 mg administration induced a significant increase in GH response to GHRH both in postmenopausal women (peak 27± 3.6 ng/ml. AUC 2, 224± 25l ng/ml/min. p<0.001) and elderly men (peak 49.7 ± 2.4 ng/ml, AUC 4, 557 ± 263 ng/ml/min, p <0.001). The GH increment, however, was greater in elderly men than in postmenopausal women (p<0.005). In young men. elderly men and postmenopausal women, PD 60 Big potentiated the action of GHRH rather than merely being additive. A similar effect was observed when a 30-mg PD dose was preadministered in elderly men and women. Our data clearly demonstrate a marked influence of age and sex on the PD potentiation of the GHRH-stimulated GH secretion. PD significantly potentiated GH responses to GHRH in young men, elderly men and postmenopausal women but not in young women.

Original languageEnglish
Pages (from-to)208-213
Number of pages6
JournalNeuroendocrinology
Volume56
Issue number2
DOIs
Publication statusPublished - 1992

Fingerprint

Pyridostigmine Bromide
Growth Hormone-Releasing Hormone
Growth Hormone
Hormones
Area Under Curve
Placebos

Keywords

  • GH
  • GHRH
  • Pyridostigmine

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Cellular and Molecular Neuroscience
  • Endocrine and Autonomic Systems

Cite this

Effects of sex and age on pyridostigmine potentiation of growth hormone-releasing hormone-induced growth hormone release. / Corsello, Salvatore M.; Tofani, Anna; Casa, Silvia Della; Rota, Carlo A.; Sciuto, Rosa; Colasanti, Simonetta; Barini, Angela; Barbarino, Antonino.

In: Neuroendocrinology, Vol. 56, No. 2, 1992, p. 208-213.

Research output: Contribution to journalArticle

Corsello, SM, Tofani, A, Casa, SD, Rota, CA, Sciuto, R, Colasanti, S, Barini, A & Barbarino, A 1992, 'Effects of sex and age on pyridostigmine potentiation of growth hormone-releasing hormone-induced growth hormone release', Neuroendocrinology, vol. 56, no. 2, pp. 208-213. https://doi.org/10.1159/000126230
Corsello, Salvatore M. ; Tofani, Anna ; Casa, Silvia Della ; Rota, Carlo A. ; Sciuto, Rosa ; Colasanti, Simonetta ; Barini, Angela ; Barbarino, Antonino. / Effects of sex and age on pyridostigmine potentiation of growth hormone-releasing hormone-induced growth hormone release. In: Neuroendocrinology. 1992 ; Vol. 56, No. 2. pp. 208-213.
@article{63e585df1d714123b1004da357580729,
title = "Effects of sex and age on pyridostigmine potentiation of growth hormone-releasing hormone-induced growth hormone release",
abstract = "Previous studies have shown that pyridostigmine (PD) is capable of increasing the growth GHRH hormone (GH) response to GH-releasing hormone (GHRH) in young healthy subjects. In Pyridostigmine order to investigate the influence of age and sex on the PD potentiation of GHRH-induced GH release, we have studied the GH response to GHRH (50 μ gi.v.) 1 h after oral administration of placebo or PD (60 mg) in 8 young healthy men (aged 19-28 years) and 8 age-matched young women (aged 18-25 years) during the follicular phase of the menstrual cycle, as well as in 8 postmenopausal women (aged 57-62 years) and 8 age-matched elderly men (aged 56-64 years). In the same subjects the effect of PD alone (60 mg p.o.) was also studied. Furthermore, in 6 postmenopausal women and 6 elderly men, the effect of a 30-mg PD oral dose on GH secretion and GH response to GHRH was evaluated with a similar protocol. The GH responses (mean ± SE) to GHRH + placebo were similar in young men (peak 20.1 ± 2 ng/ml. AUC 1, 250± 113 ng/ml/min) and women (peak 29.3 ± 2.3 tig/ml, AUC 1, 769 ± 305 ng/ml/min). PD 60 mg was capable of significantly increasing the GH response to GHRH in young men (peak 43.5± 5.1 ng/ml, AUC 3, 734± 472 ng/ml/min, p<0.005) but not in women (peak 39± 2.3 ng/ml, AUC 2.479± 205 ng/ml/min). Hie GH responses to GHRH ± placebo were also similar in postmenopausal women (peak 6.2± 0.7 ng/ml, AUC 540± 80 ng/ml/min) and age-matched men (peak 11.3± 0.6 ng/ml, AUC 763 ± 73 ng/ml/min) although these responses were significantly decreased when compared to those observed in young individuals. PD 60 mg administration induced a significant increase in GH response to GHRH both in postmenopausal women (peak 27± 3.6 ng/ml. AUC 2, 224± 25l ng/ml/min. p<0.001) and elderly men (peak 49.7 ± 2.4 ng/ml, AUC 4, 557 ± 263 ng/ml/min, p <0.001). The GH increment, however, was greater in elderly men than in postmenopausal women (p<0.005). In young men. elderly men and postmenopausal women, PD 60 Big potentiated the action of GHRH rather than merely being additive. A similar effect was observed when a 30-mg PD dose was preadministered in elderly men and women. Our data clearly demonstrate a marked influence of age and sex on the PD potentiation of the GHRH-stimulated GH secretion. PD significantly potentiated GH responses to GHRH in young men, elderly men and postmenopausal women but not in young women.",
keywords = "GH, GHRH, Pyridostigmine",
author = "Corsello, {Salvatore M.} and Anna Tofani and Casa, {Silvia Della} and Rota, {Carlo A.} and Rosa Sciuto and Simonetta Colasanti and Angela Barini and Antonino Barbarino",
year = "1992",
doi = "10.1159/000126230",
language = "English",
volume = "56",
pages = "208--213",
journal = "Neuroendocrinology",
issn = "0028-3835",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Effects of sex and age on pyridostigmine potentiation of growth hormone-releasing hormone-induced growth hormone release

AU - Corsello, Salvatore M.

AU - Tofani, Anna

AU - Casa, Silvia Della

AU - Rota, Carlo A.

AU - Sciuto, Rosa

AU - Colasanti, Simonetta

AU - Barini, Angela

AU - Barbarino, Antonino

PY - 1992

Y1 - 1992

N2 - Previous studies have shown that pyridostigmine (PD) is capable of increasing the growth GHRH hormone (GH) response to GH-releasing hormone (GHRH) in young healthy subjects. In Pyridostigmine order to investigate the influence of age and sex on the PD potentiation of GHRH-induced GH release, we have studied the GH response to GHRH (50 μ gi.v.) 1 h after oral administration of placebo or PD (60 mg) in 8 young healthy men (aged 19-28 years) and 8 age-matched young women (aged 18-25 years) during the follicular phase of the menstrual cycle, as well as in 8 postmenopausal women (aged 57-62 years) and 8 age-matched elderly men (aged 56-64 years). In the same subjects the effect of PD alone (60 mg p.o.) was also studied. Furthermore, in 6 postmenopausal women and 6 elderly men, the effect of a 30-mg PD oral dose on GH secretion and GH response to GHRH was evaluated with a similar protocol. The GH responses (mean ± SE) to GHRH + placebo were similar in young men (peak 20.1 ± 2 ng/ml. AUC 1, 250± 113 ng/ml/min) and women (peak 29.3 ± 2.3 tig/ml, AUC 1, 769 ± 305 ng/ml/min). PD 60 mg was capable of significantly increasing the GH response to GHRH in young men (peak 43.5± 5.1 ng/ml, AUC 3, 734± 472 ng/ml/min, p<0.005) but not in women (peak 39± 2.3 ng/ml, AUC 2.479± 205 ng/ml/min). Hie GH responses to GHRH ± placebo were also similar in postmenopausal women (peak 6.2± 0.7 ng/ml, AUC 540± 80 ng/ml/min) and age-matched men (peak 11.3± 0.6 ng/ml, AUC 763 ± 73 ng/ml/min) although these responses were significantly decreased when compared to those observed in young individuals. PD 60 mg administration induced a significant increase in GH response to GHRH both in postmenopausal women (peak 27± 3.6 ng/ml. AUC 2, 224± 25l ng/ml/min. p<0.001) and elderly men (peak 49.7 ± 2.4 ng/ml, AUC 4, 557 ± 263 ng/ml/min, p <0.001). The GH increment, however, was greater in elderly men than in postmenopausal women (p<0.005). In young men. elderly men and postmenopausal women, PD 60 Big potentiated the action of GHRH rather than merely being additive. A similar effect was observed when a 30-mg PD dose was preadministered in elderly men and women. Our data clearly demonstrate a marked influence of age and sex on the PD potentiation of the GHRH-stimulated GH secretion. PD significantly potentiated GH responses to GHRH in young men, elderly men and postmenopausal women but not in young women.

AB - Previous studies have shown that pyridostigmine (PD) is capable of increasing the growth GHRH hormone (GH) response to GH-releasing hormone (GHRH) in young healthy subjects. In Pyridostigmine order to investigate the influence of age and sex on the PD potentiation of GHRH-induced GH release, we have studied the GH response to GHRH (50 μ gi.v.) 1 h after oral administration of placebo or PD (60 mg) in 8 young healthy men (aged 19-28 years) and 8 age-matched young women (aged 18-25 years) during the follicular phase of the menstrual cycle, as well as in 8 postmenopausal women (aged 57-62 years) and 8 age-matched elderly men (aged 56-64 years). In the same subjects the effect of PD alone (60 mg p.o.) was also studied. Furthermore, in 6 postmenopausal women and 6 elderly men, the effect of a 30-mg PD oral dose on GH secretion and GH response to GHRH was evaluated with a similar protocol. The GH responses (mean ± SE) to GHRH + placebo were similar in young men (peak 20.1 ± 2 ng/ml. AUC 1, 250± 113 ng/ml/min) and women (peak 29.3 ± 2.3 tig/ml, AUC 1, 769 ± 305 ng/ml/min). PD 60 mg was capable of significantly increasing the GH response to GHRH in young men (peak 43.5± 5.1 ng/ml, AUC 3, 734± 472 ng/ml/min, p<0.005) but not in women (peak 39± 2.3 ng/ml, AUC 2.479± 205 ng/ml/min). Hie GH responses to GHRH ± placebo were also similar in postmenopausal women (peak 6.2± 0.7 ng/ml, AUC 540± 80 ng/ml/min) and age-matched men (peak 11.3± 0.6 ng/ml, AUC 763 ± 73 ng/ml/min) although these responses were significantly decreased when compared to those observed in young individuals. PD 60 mg administration induced a significant increase in GH response to GHRH both in postmenopausal women (peak 27± 3.6 ng/ml. AUC 2, 224± 25l ng/ml/min. p<0.001) and elderly men (peak 49.7 ± 2.4 ng/ml, AUC 4, 557 ± 263 ng/ml/min, p <0.001). The GH increment, however, was greater in elderly men than in postmenopausal women (p<0.005). In young men. elderly men and postmenopausal women, PD 60 Big potentiated the action of GHRH rather than merely being additive. A similar effect was observed when a 30-mg PD dose was preadministered in elderly men and women. Our data clearly demonstrate a marked influence of age and sex on the PD potentiation of the GHRH-stimulated GH secretion. PD significantly potentiated GH responses to GHRH in young men, elderly men and postmenopausal women but not in young women.

KW - GH

KW - GHRH

KW - Pyridostigmine

UR - http://www.scopus.com/inward/record.url?scp=0026665484&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026665484&partnerID=8YFLogxK

U2 - 10.1159/000126230

DO - 10.1159/000126230

M3 - Article

C2 - 1407375

AN - SCOPUS:0026665484

VL - 56

SP - 208

EP - 213

JO - Neuroendocrinology

JF - Neuroendocrinology

SN - 0028-3835

IS - 2

ER -